Cannabinoid signalling regulates inflammation and energy balance: The importance of the brain-gut axis

Brain, Behavior, and Immunity

Volumn 26, Issue 5, 2012, Pages 691-698

  Cluny, Nina L ^a   Reimer, Raylene A ^b   Sharkey, Keith A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cannabinoids; Energy balance; Gastrointestinal; Inflammation; Vagus

Indexed keywords

C REACTIVE PROTEIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; FATTY ACID; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADIPOGENESIS; ADIPOSE TISSUE; BRAIN; ENERGY BALANCE; FIRMICUTES; FOOD INTAKE; GANGLION; HOMEOSTASIS; HUMAN; HYPOTHALAMUS; INFLAMMATION; INSULIN RESISTANCE; INTESTINE; INTESTINE FLORA; OBESITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADIPOGENESIS; ANIMALS; BACTERIA; BRAIN; ENDOCANNABINOIDS; ENERGY METABOLISM; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATION; METAGENOME; OBESITY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION;

EID: 84861971975     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.01.004     Document Type: Review

References (79)

1. Agudo J., Martin M., Roca C., Molas M., Bura A.S., Zimmer A., Bosch F., Maldonado R. Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia 2010, 53:2629-2640.
2. Alexander S.P., Kendall D.A. The life cycle of the endocannabinoids: formation and inactivation. Curr. Top. Behav. Neurosci. 2009, 1:3-35.
3. Backhed F., Ding H., Wang T., Hooper L.V., Koh G.Y., Nagy A., Semenkovich C.F., Gordon J.I. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15718-15723.
4. Barbier De La Serre C., Ellis C.L., Lee J., Hartman A.L., Rutledge J.C., Raybould H.E. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299:G440-G448.
5. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand J.P., Le Fur G., Oury-Donat F., Soubrie P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 2003, 63:908-914.
6. Bluher M., Engeli S., Kloting N., Berndt J., Fasshauer M., Batkai S., Pacher P., Schon M.R., Jordan J., Stumvoll M. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006, 55:3053-3060.
7. Bueter M., Le Roux C.W. Gastrointestinal hormones, energy balance and bariatric surgery. Int. J. Obes. (Lond.) 2011, 35(Suppl. 3):S35-S39.
8. Burdyga G., Lal S., Varro A., Dimaline R., Thompson D.G., Dockray G.J. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J. Neurosci. 2004, 24:2708-2715.
9. Burdyga G., Varro A., Dimaline R., Thompson D.G., Dockray G.J. Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics, and role in influencing neurochemical phenotype. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 5:6-7.
10. Calegari V.C., Torsoni A.S., Vanzela E.C., Araujo E.P., Morari J., Zoppi C.C., Sbragia L., Boschero A.C., Velloso L.A. Inflammation of the hypothalamus leads to defective pancreatic islet function. J. Biol. Chem. 2011, 286:12870-12880.
11. Cani P.D., Bibiloni R., Knauf C., Waget A., Neyrinck A.M., Delzenne N.M., Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
12. Cani P.D., Delzenne N.M. The gut microbiome as therapeutic target. Pharmacol. Ther. 2011, 130:202-212.
13. Cani P.D., Possemiers S., Van De Wiele T., Guiot Y., Everard A., Rottier O., Geurts L., Naslain D., Neyrinck A., Lambert D.M., Muccioli G.G., Delzenne N.M. Changes in gut microbiota control inflammation in obese mice through a mechanism involving Glp-2-driven improvement of gut permeability. Gut 2009, 58:1091-1103.
14. Chambers A.P., Koopmans H.S., Pittman Q.J., Sharkey K.A. Am 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion. Br. J. Pharmacol. 2006, 147:109-116.
15. Chambers A.P., Sharkey K.A., Koopmans H.S. Cannabinoid (Cb)1 receptor antagonist, Am 251, causes a sustained reduction of daily food intake in the rat. Physiol. Behav. 2004, 82:863-869.
16. Cluny N.L., Chambers A.P., Vemuri V.K., Wood J.T., Eller L.K., Freni C., Reimer R.A., Makriyannis A., Sharkey K.A. The neutral cannabinoid Cb receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol. Biochem. Behav. 2011, 97:537-543.
17. Cluny N.L., Chambers A.P., Vemuri V.K., Wood J.T., Eller L.K., Freni C., Reimer R.A., Makriyannis A., Sharkey K.A. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted, cannabinoid CB1/CB2 receptor agonist inhibits gastrointestinal motility, but has no effect on experimental colitis in mice. Pharmacol. Biochem. Behav. 2011, 97:537-543.
18. Cluny N.L., Vemuri V.K., Chambers A.P., Limebeer C.L., Bedard H., Wood J.T., Lutz B., Zimmer A., Parker L.A., Makriyannis A., Sharkey K.A. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br. J. Pharmacol. 2010, 161:629-642.
19. Collins S.M., Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 2009, 136:2003-2014.
20. Colombo G., Agabio R., Diaz G., Lobina C., Reali R., Gessa G.L. Appetite suppression and weight loss after the cannabinoid antagonist Sr 141716. Life Sci. 1998, 63:L113-L117.
21. Cota D., Sandoval D.A., Olivieri M., Prodi E., D'alessio D.A., Woods S.C., Seeley R.J., Obici S. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring) 2009, 17:1641-1645.
22. Croci T., Zarini E. Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. Br. J. Pharmacol. 2007, 150:559-566.
23. Das U.N. Obesity: genes, brain, gut, and environment. Nutrition 2010, 26:459-473.
24. De Souza C.T., Araujo E.P., Bordin S., Ashimine R., Zollner R.L., Boschero A.C., Saad M.J., Velloso L.A. Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology 2005, 146:4192-4199.
25. Delzenne N.M., Cani P.D., Daubioul C., Neyrinck A.M. Impact of inulin and oligofructose on gastrointestinal peptides. Br. J. Nutr. 2005, 93(Suppl. 1):S157-S161.
26. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
27. Deveaux V., Cadoudal T., Ichigotani Y., Teixeira-Clerc F., Louvet A., Manin S., Nhieu J.T., Belot M.P., Zimmer A., Even P., Cani P.D., Knauf C., Burcelin R., Bertola A., Le Marchand-Brustel Y., Gual P., Mallat A., Lotersztajn S. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One 2009, 4:e5844.
28. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev. Physiol. Biochem. Pharmacol. 2008, 160:1-24.
29. Di Marzo V., Capasso R., Matias I., Aviello G., Petrosino S., Borrelli F., Romano B., Orlando P., Capasso F., Izzo A.A. The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br. J. Pharmacol. 2008, 153:1272-1280.
30. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822-825.
31. Dipatrizio N.V., Astarita G., Schwartz G., Li X., Piomelli D. Endocannabinoid signal in the gut controls dietary fat intake. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12904-12908.
32. Dockray G.J., Burdyga G. Plasticity in vagal afferent neurones during feeding and fasting: mechanisms and significance. Acta Physiol. (Oxf.) 2011, 201:313-321.
33. Fresno M., Alvarez R., Cuesta N. Toll-like receptors, inflammation, metabolism and obesity. Arch. Physiol. Biochem. 2011, 117:151-164.
34. Fu J., Astarita G., Gaetani S., Kim J., Cravatt B.F., Mackie K., Piomelli D. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J. Biol. Chem. 2007, 282:1518-1528.
35. Geurts L., Lazarevic V., Derrien M., Everard A., Van Roye M., Knauf C., Valet P., Girard M., Muccioli G.G., Francois P., De Vos W.M., Schrenzel J., Delzenne N.M., Cani P.D. Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol. 2011, 2:149.
36. Gómez R., Navarro M., Ferrer B., Trigo J.M., Bilbao A., Del Arco I., Cippitelli A., Nava F., Piomelli D., Rodriguez De Fonseca F. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J. Neurosci. 2002, 22:9612-9617.
37. Izzo A.A., Piscitelli F., Capasso R., Aviello G., Romano B., Borrelli F., Petrosino S., Di Marzo V. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br. J. Pharmacol. 2009, 158:451-461.
38. Jarai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., Zimmer A.M., Bonner T.I., Buckley N.E., Mezey E., Razdan R.K., Zimmer A., Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:14136-14141.
39. Jbilo O., Ravinet-Trillou C., Arnone M., Buisson I., Bribes E., Peleraux A., Penarier G., Soubrie P., Le Fur G., Galiegue S., Casellas P. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 2005, 19:1567-1569.
40. Kirkham T.C., Williams C.M., Fezza F., Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 2002, 136:550-557.
41. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
42. LoVerme J., Duranti A., Tontini A., Spadoni G., Mor M., Rivara S., Stella N., Xu C., Tarzia G., Piomelli D. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg. Med. Chem. Lett. 2009, 19:639-643.
43. Lumeng C.N., Saltiel A.R. Inflammatory links between obesity and metabolic disease. J. Clin. Invest 2011, 121:2111-2117.
44. Mackie K. Cannabinoid receptors: where they are and what they do. J. Neuroendocrinol. 2008, 20(Suppl. 1):10-14.
45. Matias I., Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol. Metab. 2007, 18:27-37.
46. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., Petrosino S., Hoareau L., Festy F., Pasquali R., Roche R., Maj M., Pagotto U., Monteleone P., Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 2006, 91:3171-3180.
47. Matias I., Petrosino S., Racioppi A., Capasso R., Izzo A.A., Di Marzo V. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol. Cell Endocrinol. 2008, 286:S66-S78.
48. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50:83-90.
49. Monory K., Lutz B. Genetic models of the endocannabinoid system. Curr. Top. Behav. Neurosci. 2009, 1:111-139.
50. Muccioli G.G. Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov. Today 2010, 15:474-483.
51. Muccioli G.G., Naslain D., Backhed F., Reigstad C.S., Lambert D.M., Delzenne N.M., Cani P.D. The endocannabinoid system links gut microbiota to adipogenesis. Mol. Syst. Biol. 2010, 6:392.
52. Nefti W., Chaumontet C., Fromentin G., Tome D., Darcel N. A high-fat diet attenuates the central response to within-meal satiation signals and modifies the receptor expression of vagal afferents in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296:R1681-R1686.
53. Nogueiras R., Veyrat-Durebex C., Suchanek P.M., Klein M., Tschop J., Caldwell C., Woods S.C., Wittmann G., Watanabe M., Liposits Z., Fekete C., Reizes O., Rohner-Jeanrenaud F., Tschop M.H. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 2008, 57:2977-2991.
54. Onaivi E.S., Carpio O., Ishiguro H., Schanz N., Uhl G.R., Benno R. Behavioral effects of CB2 cannabinoid receptor activation and its influence on food and alcohol consumption. Ann. N. Y. Acad. Sci. 2008, 1139:426-433.
55. Osei-Hyiaman D., Depetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., Harvey-White J., Mackie K., Offertaler L., Wang L., Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest 2005, 115:1298-1305.
56. Parnell J.A., Reimer R.A. Prebiotic fibres dose-dependently increase satiety hormones and alter Bacteroidetes and Firmicutes in lean and obese JCR:LA-cp rats. Br. J. Nutr. 2011, 1-13.
57. Patel K.D., Davison J.S., Pittman Q.J., Sharkey K.A. Cannabinoid Cb(2) receptors in health and disease. Curr. Med. Chem. 2010, 17:1393-1410.
58. Paulino G., Barbier De La Serre C., Knotts T.A., Oort P.J., Newman J.W., Adams S.H., Raybould H.E. Increased expression of receptors for orexigenic factors in nodose ganglion of diet-induced obese rats. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E898-E903.
59. Pavon F.J., Bilbao A., Hernandez-Folgado L., Cippitelli A., Jagerovic N., Abellan G., Rodriguez-Franco M.A., Serrano A., Macias M., Gomez R., Navarro M., Goya P., Rodriguez De Fonseca F. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole - Lh 21. Neuropharmacology 2006, 51:358-366.
60. Pertwee R.G., Howlett A.C., Abood M.E., Alexander S.P., Di M., Elphick M.R., Greasley P.J., Hansen H.S., Kunos G., Mackie K., Mechoulam R., Ross R.A. International Union of Basic and Clinical Pharmacology. Lxxix. Cannabinoid receptors and their ligands: beyond Cb and Cb. Pharmacol. Rev. 2010, 62:588-631.
61. Purkayastha S., Zhang H., Zhang G., Ahmed Z., Wang Y., Cai D. Neural dysregulation of peripheral insulin action and blood pressure by brain endoplasmic reticulum stress. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:2939-2944.
62. Ravinet Trillou C., Delgorge C., Menet C., Arnone M., Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 2004, 28:640-648.
63. Rhee S.H., Pothoulakis C., Mayer E.A. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat. Rev. Gastroenterol. Hepatol. 2009, 6:306-314.
64. Rodriguez De Fonseca F., Navarro M., Gomez R., Escuredo L., Nava F., Fu J., Murillo-Rodriguez E., Giuffrida A., LoVerme J., Gaetani S., Kathuria S., Gall C., Piomelli D. An anorexic lipid mediator regulated by feeding. Nature 2001, 414:209-212.
65. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest 2006, 116:3015-3025.
66. Sink K.S., MCLaughlin P.J., Wood J.A., Brown C., Fan P., Vemuri V.K., Peng Y., Olszewsk A.T., Thakur G.A., Makriyannis A., Parker L.A., Salamone J.D. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 2008, 33:946-955.
67. Sopasakis V.R., Sandqvist M., Gustafson B., Hammarstedt A., Schmelz M., Yang X., Jansson P.A., Smith U. High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes. Res. 2004, 12:454-460.
68. Starowicz K.M., Cristino L., Matias I., Capasso R., Racioppi A., Izzo A.A., Di Marzo V. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 2008, 16:553-565.
69. Suganami T., Nishida J., Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2062-2068.
70. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 1995, 215:89-97.
71. Suzuki K., Simpson K.A., Minnion J.S., Shillito J.C., Bloom S.R. The role of gut hormones and the hypothalamus in appetite regulation. Endocr. J. 2010, 57:359-372.
72. Thaler J.P., Schwartz M.W. Minireview: inflammation and obesity pathogenesis: the hypothalamus heats up. Endocrinology 2010, 151:4109-4115.
73. Timofeeva E., Baraboi E.D., Poulin A.M., Richard D. Palatable high-energy diet decreases the expression of cannabinoid type 1 receptor messenger RNA in specific brain regions in the rat. J. Neuroendocrinol. 2009, 21:982-992.
74. Tsukumo D.M., Carvalho-Filho M.A., Carvalheira J.B., Prada P.O., Hirabara S.M., Schenka A.A., Araujo E.P., Vassallo J., Curi R., Velloso L.A., Saad M.J. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007, 56:1986-1998.
75. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
76. Vitseva O.I., Tanriverdi K., Tchkonia T.T., Kirkland J.L., Mcdonnell M.E., Apovian C.M., Freedman J., Gokce N. Inducible Toll-like receptor and Nf-kappaB regulatory pathway expression in human adipose tissue. Obesity (Silver Spring) 2008, 16:932-937.
77. Wang Q., Perrard X.D., Perrard J.L., Mansoori A., Smith C.W., Ballantyne C.M., Wu H. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity. Obesity (Silver Spring) 2011, 19:505-513.
78. Weisberg S.P., Mccann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest 2003, 112:1796-1808.
79. Wiley J.L., Burston J.J., Leggett D.C., Alekseeva O.O., Razdan R.K., Mahadevan A., Martin B.R. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br. J. Pharmacol. 2005, 145:293-300.